Article in Pharmaceuticals (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
10 authors.
Ana Alonso-PérezMusculoskeletal Pathology Group, Laboratory 18, Health Research Institute of Santiago de Compostela (IDIS), Santiago University Clinical Hospital SERGAS, 15706 Santiago de Compostela, Spain.ORCID 0000-0001-5830-0960
Eloi Franco-TrepatMusculoskeletal Pathology Group, Laboratory 18, Health Research Institute of Santiago de Compostela (IDIS), Santiago University Clinical Hospital SERGAS, 15706 Santiago de Compostela, Spain.ORCID 0000-0001-7514-4672
María Guillán-FrescoMusculoskeletal Pathology Group, Laboratory 18, Health Research Institute of Santiago de Compostela (IDIS), Santiago University Clinical Hospital SERGAS, 15706 Santiago de Compostela, Spain.ORCID 0000-0002-6269-5130
Miriam López-FagúndezMusculoskeletal Pathology Group, Laboratory 18, Health Research Institute of Santiago de Compostela (IDIS), Santiago University Clinical Hospital SERGAS, 15706 Santiago de Compostela, Spain.ORCID 0000-0002-4577-737X
Andrés Pazos-PérezMusculoskeletal Pathology Group, Laboratory 18, Health Research Institute of Santiago de Compostela (IDIS), Santiago University Clinical Hospital SERGAS, 15706 Santiago de Compostela, Spain.
Verónica LópezMusculoskeletal Pathology Group, Laboratory 18, Health Research Institute of Santiago de Compostela (IDIS), Santiago University Clinical Hospital SERGAS, 15706 Santiago de Compostela, Spain.
Antonio SalasGrupo de Investigación en Genética, Vacunas, Infecciones y Pediatría (GENVIP), Health Research Institute of Santiago de Compostela (IDIS), Santiago University Clinical Hospital SERGAS, 15706 Santiago de Compostela, Spain.ORCID 0000-0002-2336-702X
Federico Martinón-TorresGrupo de Investigación en Genética, Vacunas, Infecciones y Pediatría (GENVIP), Health Research Institute of Santiago de Compostela (IDIS), Santiago University Clinical Hospital SERGAS, 15706 Santiago de Compostela, Spain.ORCID 0000-0002-9023-581X
Alberto A Jorge-MoraMusculoskeletal Pathology Group, Laboratory 18, Health Research Institute of Santiago de Compostela (IDIS), Santiago University Clinical Hospital SERGAS, 15706 Santiago de Compostela, Spain.
Rodolfo GómezMusculoskeletal Pathology Group, Laboratory 18, Health Research Institute of Santiago de Compostela (IDIS), Santiago University Clinical Hospital SERGAS, 15706 Santiago de Compostela, Spain.ORCID 0000-0002-1309-1023
Funding
Axencia Galega de Innovacion IN607B-2022-09Fundación Española para la Ciencia y la Tecnología PRECIPITA PR250Fundación Instituto de Investigación Sanitaria de Santiago de Compostela IDIS 2019-2022Fundación Mutua Madrileña MMA2018Fundación Mutua Madrileña MMA2020Instituto de Salud Carlos III CP15/00007Instituto de Salud Carlos III CPII20/00026Instituto de Salud Carlos III FI20/00210Instituto de Salud Carlos III PI16/01870Instituto de Salud Carlos III PI19/01446Instituto de Salud Carlos III PI22/00407Instituto de Salud Carlos III PT20/00009Instituto de Salud Carlos III RD21/0002/0025Ministerio de Universidades FPU17/01706
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Repurposed Drugs for Heterotopic Ossification Management: Revitalizing Therapeutic Strategies. · full record | OpenQuestion